|
Unani formulation | Method/model | Extract use/dosage form | Control/organism tested | Result | Pharmacological application | Ref. |
|
Preclinical studies |
Arq-Ajeeb | In vivo (rats) | 0.07 ml and 0.14 ml/kg, p.o. | Charcoal administration | Reduce diarrhea in rats | Anti-diarrheal activity | [51] |
Compound preparation of sesame oil, camphor, and honey | Animal (rat) | Daily dressing with extract | Oil Vaseline | Maximal healing was noticed in the test group | Healing effect of second-degree burn | [52] |
Arq Ajīb contains methanol, camphor | In silico approach | Inhibits SARS-CoV-2 spike glycoprotein and main protease | — | Good interactions and binding affinities with 3CLpro and S glycoprotein | Inhibitory effect on SARS-CoV-2 | [53] |
Extract C. camphora and Ziziphora tenuior | In vitro mice liver | 3, 5, 10, 25, 50, and 100 mg/ml of extracts | — | The extract exhibited dose-dependent and time-dependent antiparasitic effects | Anti-parasitic and immunomodulatory | [54] |
Clinical studies |
Marham-i-Raal | Single-arm pre- and posttreatment study | 2 gm on episiotomy wound | — | REEDA score decreased, and VAS score decreased | Episiotomy wound healing and pain reduction | [55] |
Marham-i-Raal | Case study | External application (3 months) (ointment) | — | Completely heal foot ulcer | Chronic wound healing | [21] |
Arq Ajib | Clinical study | Liquid application | — | Decrease in VAS score for pain intensity | Headache | [56] |
Composition of A. indica and C. camphora | Controlled clinical trial | Oral and topical | Psoralen plus ultraviolet A (PUVA) solution | In individuals with moderate-to-severe CPP, test medications that are efficacious and well-tolerated | Chronic plaque psoriasis | [57] |
|